Literature DB >> 16289777

Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant.

Shinya Takatsuka1, Takeo Kitazawa, Takahiro Morita, Yuji Horikiri, Hiroyuki Yoshino.   

Abstract

The effect of co-administration of a mucolytic agent with a penetration enhancer was assessed on the intestinal absorption of poorly absorbed hydrophilic compounds. Fluorescein isothiocyanate-labeled dextran with average molecular weight of ca. 4.4 kDa (FD-4) was used as a model compound, and N-acetylcysteine (NAC) was used as a mucolytic agent. Sodium caprate (C10), tartaric acid (TA), sodium taurodeoxycholate (TDC), sodium dodecyl sulfate (SDS), p-t-octyl phenol polyoxyethylene-9.5 (Triton X-100, TX-100) were selected as penetration enhancers with different mechanisms of action. Various dosing solutions containing a penetration enhancer in the absence or in the presence of NAC were directly administered into the exposed rat jejunum, and the bioavailability of FD-4 up to 2 h was determined. The extent of improvement by co-administration was highly dependent on the penetration enhancer species applied. The observed enhancement was thought to result from the mucolytic activity of NAC, which can reduce the mucus viscosity and facilitate the penetration of FD-4 to mucosal membrane. Among the combinations tested, the simultaneous administration of NAC and TX-100 provided the highest enhancement (22.5-fold) of intestinal FD-4 absorption compared to the control. Although the detailed mechanism for the observed drastic improvement is unclear, one possible reason was thought to be due to the improved diffusivity of TX-100 micellar system in the mucus layer. All these results suggest that the combination of a mucolytic agent and a non-ionic surfactant may have potential as an enhancing system for peroral delivery of poorly absorbed hydrophilic compounds like protein and peptide drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289777     DOI: 10.1016/j.ejpb.2005.07.008

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  Safe and effective permeation enhancers for oral drug delivery.

Authors:  Kathryn Whitehead; Natalie Karr; Samir Mitragotri
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

2.  Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules.

Authors:  Anne-Claire Groo; Kristina Mircheva; Jérôme Bejaud; Caroline Ailhas; Ivan Panaiotov; Patrick Saulnier; Tzvetanka Ivanova; Frederic Lagarce
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

Review 3.  Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems.

Authors:  Deepak A Subramanian; Robert Langer; Giovanni Traverso
Journal:  J Nanobiotechnology       Date:  2022-08-06       Impact factor: 9.429

4.  Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.

Authors:  Viraj Mane; Silvia Muro
Journal:  Int J Nanomedicine       Date:  2012-08-01

Review 5.  Trends in drug delivery through tissue barriers containing tight junctions.

Authors:  Christian Tscheik; Ingolf E Blasig; Lars Winkler
Journal:  Tissue Barriers       Date:  2013-04-01

Review 6.  Quaternary Ammonium Chitosans: The Importance of the Positive Fixed Charge of the Drug Delivery Systems.

Authors:  Angela Fabiano; Denise Beconcini; Chiara Migone; Anna Maria Piras; Ylenia Zambito
Journal:  Int J Mol Sci       Date:  2020-09-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.